Daily Stock Opinions and Ratings

Opinions

Ross Healy Bausch Health Companies Inc. BHC-T BUY Jul 11, 2019

After a stunning fall from grace, there's been a stunning recovery. FMV is 127% higher than it's currently trading, and it's been there before. Looks like a resurrection.

Ross Healy

Unknown

Unlock Rating

$31.210

Stock price when the opinion was issued

Healthcare

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

BUY

A covered call He likes covered calls and you can do it with BHC. Write them and take the premium here. BHC has been rangebound, but demographics favour health stocks. However, governments will limit pricing of health services.

BUY

If it can continue on volume, it looks very positive. It has built a nice base and it’s worthy of a buy. Support should be around $27. He would aim for the 100 day moving average.

WATCH

Kudos to the management for selling off businesses and paying down debt. It may be something investor should look at again.

DON'T BUY

He gives managements kudos for restructuring the business. They are still heavily indebted. He is looking for valuation with consistent cashflow which this is not. It's not the type of company he looks at.

BUY ON WEAKNESS

He likes and owns it. It is basically the old broken valiant. He likes the space and he likes the big time drugs. These stocks offer incredible value. His model price is $72.41, 122% upside. Buy it when it comes down again. Buy half on the way in.

DON'T BUY

The old Valent Pharmaceutical company. When it became over-levered it struggled. He thinks there are far better opportunities in the health care space.

DON'T BUY

Spinning out the eyecare side. Better to go to the US with bigger, safer stocks or one of the ETFs.

DON'T BUY

A turnaround story. They have done a good job stabilizing the company. It has a lot of debt and legal issues to resolve. The debt levels are probably still too high. They are spinning out their eyecare business which is their crown jewel. There is some more work to do before taking a position.

DON'T BUY

He won't offer a buy-sell-hold verdict. BHC has done a good reorganization. There's talk of spinning out their eye division. Has a 6.5% EBITDA-to-debt ratio, so there's still some debt. They're still restructuring, so there will be little growth.

SELL

Kudos to the new executive at delevering and cleaning things up. Inexpensive valuation. Still a lot of debt. A turnaround story. 3% of your portfolio is a bit heavy. Add some diversity. Had a great move. Be cautious.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

Ross Healy Bausch Health Companies Inc. BHC-T BUY Jul 11, 2019

You might be interested:

Bausch Health Companies Inc.(BHC-T)

Bausch Health Companies Inc.(BHC-T)

Bausch Health Companies Inc.(BHC-T)

Bausch Health Companies Inc.(BHC-T)

Bausch Health Companies Inc.(BHC-T)

Bausch Health Companies Inc.(BHC-T)

Bausch Health Companies Inc.(BHC-T)

Bausch Health Companies Inc.(BHC-T)

Bausch Health Companies Inc.(BHC-T)

Bausch Health Companies Inc.(BHC-T)

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals

Most Recent Experts

Bruce Murray

The Panic-Proof Portfolio (Stockchase Research)

The Weekly Buzzing Stocks by Billy Kawasaki

Chris Blumas

Stockchase Insights